AKEBIA THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase Decrease In Operating Lease Liability of -$2.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.19M.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.42M.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.39M.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.36M.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$5.40M.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$4.49M.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$4.96M, a 314.76% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was $2.31M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.61M 10-Q · filed 2026-08-05 | -$4.00M derived: sum of 3 quarters · filed 2026-08-05 | -$5.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.42M 10-Q · filed 2026-05-07 | -$2.81M derived: sum of 2 quarters · filed 2026-05-07 | -$4.17M derived: sum of 3 quarters · filed 2026-05-07 | -$5.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.75M derived: sum of 2 quarters · filed 2026-02-26 | -$4.09M derived: sum of 3 quarters · filed 2026-08-05 | -$5.40M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.70M derived: sum of 2 quarters · filed 2026-08-05 | -$4.01M 10-Q · filed 2025-11-10 | -$5.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.65M 10-Q · filed 2026-08-05 | -$3.93M derived: sum of 3 quarters · filed 2026-08-05 | -$5.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.31M 10-Q · filed 2026-05-07 | -$2.59M derived: sum of 2 quarters · filed 2026-05-07 | -$3.84M derived: sum of 3 quarters · filed 2026-05-07 | -$5.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.53M derived: sum of 2 quarters · filed 2026-02-26 | -$3.76M derived: sum of 3 quarters · filed 2026-02-26 | -$4.49M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.48M derived: sum of 2 quarters · filed 2025-11-10 | -$3.21M 10-Q · filed 2025-11-10 | -$9.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.96M 10-Q · filed 2025-08-07 | -$8.05M derived: sum of 3 quarters · filed 2026-02-26 | -$7.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$731.00K 10-Q · filed 2025-05-08 | -$6.82M derived: sum of 2 quarters · filed 2026-02-26 | -$6.73M derived: sum of 3 quarters · filed 2026-02-26 | -$6.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.00M derived: sum of 2 quarters · filed 2026-02-26 | -$5.61M derived: sum of 3 quarters · filed 2026-02-26 | -$4.96M 10-K · filed 2026-02-26 |
| 2023-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $477.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.13M 10-Q · filed 2024-11-07 | $1.67M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.03M 10-Q · filed 2024-08-08 | $1.57M derived: sum of 3 quarters · filed 2024-08-08 | $2.14M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $651.00K 10-Q · filed 2024-05-09 | $1.19M derived: sum of 2 quarters · filed 2024-05-09 | $1.76M derived: sum of 3 quarters · filed 2024-05-09 | $2.35M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.11M derived: sum of 2 quarters · filed 2024-03-14 | $1.70M derived: sum of 3 quarters · filed 2024-03-14 | $2.31M 10-K · filed 2024-03-14 |
| 2022-09-30 | $566.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.16M derived: sum of 2 quarters · filed 2023-11-08 | $1.77M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $589.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28 | $1.21M 10-Q · filed 2023-08-28 | ||
| 2022-03-31 | $616.00K 10-Q · filed 2023-05-08 | |||
| 2021-09-30 | $369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $766.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.17M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $804.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $407.00K 10-Q · filed 2022-05-09 | |||
| 2020-09-30 | $1.03M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |